Literature DB >> 30766102

SGLT2 Inhibitors for Type 2 Diabetes Mellitus Treatment.

Raymond A Plodkowski1, Megan E McGarvey1, Heather M Huribal1, Keith Reisinger-Kindle1, Bradley Kramer1, Mordecai Solomon1, Quang T Nguyen1.   

Abstract

SGLT2 inhibitors are plausible second-line drugs that provide powerful additional A1c-lowering effects while inducing weight loss without hypoglycemia.

Entities:  

Year:  2015        PMID： 30766102      PMCID： PMC6375399     

Source DB:  PubMed          Journal:  Fed Pract        ISSN： 1078-4497


  1 in total

Review 1.  Comparison of Cardiovascular Outcomes Between Dapagliflozin and Empagliflozin in Patients With Type 2 Diabetes: A Meta-Analysis.

Authors:  Rahat A Memon; Hanieh Akbariromani; Rimsha R Vohra; Hayan Kundi; Rao Faraz Saleem; Muhammad Abuzar Ghaffari; Donald Haas; Areeba Khan
Journal:  Cureus       Date:  2022-07-26
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.